Executive president of MindMed, Miri Halperin Wernli, PhD, added: “LSD and psilocybin have recently become promising candidates for the treatment of various psychiatric and neurologic disorders, and thus a deeper understanding of their differential subjective effects in humans is needed. 

Cerevance has developed its proprietary, Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to analyze postmortem human brain tissues to produce rich cell type–specific data sets. 

Portage Biotech: Clinical-stage oncology company dedicated to sourcing and acquiring the most promising early-stage assets available to build a pipeline of first-in-class/best-in-class therapeutic candidates. Currently, has well-established partnerships with both Bristol Myers Squibb and Merck.

Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.

The FDA has granted investigational device exemption to medical diagnostics company Check-Cap for a two-part pivotal study to evaluate C-Scan, a new screening test that detects precancerous polyps.

There are currently no approved treatments for the prevention of recurrent VVC, but Scynexis said it will submit the new phase 3 data to the FDA in the first half of 2022 and expects that ibrexafungerp tablets will be approved for this indication by the end of the year.

Cancer intervention and prevention company Check Cap is developing new, low-invasive ingestible capsule technology that aims to address issues associated with preventive screenings for colonoscopies.